new_0222_0475|VIRX|Short Name|0|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return
new_0222_0475|VIRX|Long Name|1|1|Viracta Therapeutics Inc Total Current Assets (Quarterly) (USD)|Viracta Therapeutics Inc Cash and Short Term Investments (Quarterly) (USD)|Viracta Therapeutics Inc Inventories (Quarterly) (USD)|Viracta Therapeutics Inc Net PP&E (Quarterly) (USD)|Viracta Therapeutics Inc Goodwill and Intangibles (Quarterly) (USD)|Viracta Therapeutics Inc Total Liabilities (Quarterly) (USD)|Viracta Therapeutics Inc Total Current Liabilities (Quarterly) (USD)|Viracta Therapeutics Inc Total Long Term Liabilities (Quarterly) (USD)|Viracta Therapeutics Inc Total Deposits (Quarterly) (USD)|Viracta Therapeutics Inc Book Value (Quarterly) (USD)|Viracta Therapeutics Inc Retained Earnings (Quarterly) (USD)|Viracta Therapeutics Inc Treasury Stock (Quarterly) (USD)|Viracta Therapeutics Inc EV to Revenues|Viracta Therapeutics Inc EV to Earnings|Viracta Therapeutics Inc EV to Free Cash Flow|Viracta Therapeutics Inc EV to Assets (Quarterly)|Viracta Therapeutics Inc PS Ratio|Viracta Therapeutics Inc PE Ratio|Viracta Therapeutics Inc Price to Book Value|Viracta Therapeutics Inc PEG Ratio|Viracta Therapeutics Inc Debt to Equity Ratio|Viracta Therapeutics Inc Dividend Yield|Viracta Therapeutics Inc Shareholder Yield (TTM)|Viracta Therapeutics Inc Percent of Shares Outstanding Short|Viracta Therapeutics Inc Total Receivables (Quarterly) (USD)|Viracta Therapeutics Inc Total Payables (Quarterly) (USD)|Viracta Therapeutics Inc Total Capital Stock (Quarterly) (USD)|Viracta Therapeutics Inc Return on Invested Capital|Viracta Therapeutics Inc Quality Ratio Score|Viracta Therapeutics Inc Momentum Score|Viracta Therapeutics Inc Beta (1Y)|Viracta Therapeutics Inc Sustainable Growth Rate (TTM)|Viracta Therapeutics Inc Institutional Investor Ownership Percentage|Viracta Therapeutics Inc Average Diluted Shares Outstanding (Quarterly)|Viracta Therapeutics Inc Total Employees (Annual)|Viracta Therapeutics Inc EPS Diluted (Quarterly) (USD)|Viracta Therapeutics Inc Shares Outstanding|Viracta Therapeutics Inc Repurchase of Capital Stock (Quarterly) (USD)|Viracta Therapeutics Inc Ordinary Shares Number (Quarterly)|Viracta Therapeutics Inc Payout Ratio|Viracta Therapeutics Inc Quick Ratio (Quarterly)|Viracta Therapeutics Inc Normalized Diluted EPS (Quarterly) (USD)|Viracta Therapeutics Inc Stock Buybacks (Quarterly) (USD)|Viracta Therapeutics Inc Effective Tax Rate (TTM)|Viracta Therapeutics Inc Return on Equity|Viracta Therapeutics Inc Net Income (TTM) (USD)|Viracta Therapeutics Inc Revenue (TTM) (USD)|Viracta Therapeutics Inc Dividend Per Share (Quarterly) (USD)|Viracta Therapeutics Inc Revenue (Quarterly) (USD)|Viracta Therapeutics Inc Gross Profit (Quarterly) (USD)|Viracta Therapeutics Inc SG&A Expense (Quarterly) (USD)|Viracta Therapeutics Inc Pre-Tax Income (Quarterly) (USD)|Viracta Therapeutics Inc Net Income (Quarterly) (USD)|Viracta Therapeutics Inc Net Interest Income (Quarterly) (USD)|Viracta Therapeutics Inc Price (USD)|Viracta Therapeutics Inc Total Return Price (USD)|Viracta Therapeutics Inc Enterprise Value (USD)|Viracta Therapeutics Inc 30-Day Average Daily Volume|Viracta Therapeutics Inc 1 Year Price Returns (Daily)
new_0222_0475|VIRX|Unit|2|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric
new_0222_0475|VIRX||4|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|quarterly|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|quarterly
new_0222_0475|VIRX||5|5|91.5|91.5|0|91.5|0|91.5|91.5|91.5|0|91.5|91.5|0|0|0|1.44090909091|0|0|0|1.44090909091|0|0|1.43319838057|0|15.4090909091|0|91.5|91.5|0|0|0|0|0|30.6363636364|109.6|0|109.6|35.8571428571|0|91.5|0|0|109.6|109.6|0|0|91.5|0|0|0|0|109.6|109.6|109.6|109.6|1.43319838057|1.43319838057|1.44090909091|1.43119266055|0
new_0222_0475|VIRX||6|6|2|2|0|2|0|2|2|2|0|2|2|0|0|0|220|0|0|0|220|0|0|247|0|22|0|2|2|0|0|0|0|0|11|5|0|5|7|0|2|0|0|5|5|0|0|2|0|0|0|0|5|5|5|5|247|247|220|218|0
new_0222_0475|VIRX||7|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily
new_0222_0475|VIRX|202003|202003|202003||||||||||||||||||||||||||||||||||36.9946||-0.1194||||||-0.1194|0||||||||1.011|-4.417|-4.417|0.04|||||
new_0222_0475|VIRX|202006|202006|202006||||||||||||||||||||||||||||||||||36.9946||-0.1145||||||-0.1145|0||||||||0.879|-4.236|-4.236|0.004|||||
new_0222_0475|VIRX|202009|202009|202009||||||||||||||||||||||||||||||||||36.9946||-0.1103||||||-0.1103|-0.046||||||||0.887|-4.079|-4.079|-0.065|||||
new_0222_0475|VIRX|202102|202012|202012||||||||||||||||||||||0||1.7967|||||||||7.4629||||36.9946||||||||||||||||||15.7|15.7|||
new_0222_0475|VIRX|202103|202103|202103|132.304|129.181||1.078||11.465|6.265|5.2||119.292|-130.146||||-25.0014||||2.8718|||0||1.7625||1.571|5.456||||||43.3423|15.1667||-5.22|37.0363||37.0363|||0.35|-62.317|||-91.963|||||3.84|-79.231|-79.231|-0.099|9.25|9.25|224.0628||
new_0222_0475|VIRX|202104|202103|202103|||||||||||||||-31.4069||||3.353|||0||1.9613|||||||||43.6667||||||||||||||||||||||10.8|10.8|281.469|347950.3667|
new_0222_0475|VIRX|202105|202103|202103|||||||||||||||-29.7366||||3.2276|||0||2.6106|||||||||44.127||||37.0927||||||||||||||||||10.38|10.38|266.4992|356649.9|
new_0222_0475|VIRX|202106|202106|202106|125.142|122.721||0.857||11.582|6.953|4.629||111.645|-139.316||||-25.8339||||3.7725|||0||6.135||2.566|5.456||||||53.6138|37.2214||-0.25|37.1408||37.1408|||-0.2569|-0.002|||-96.716|||||3.871|-9.17|-9.17|-0.11|11.34|11.34|308.8957|474897.5333|
new_0222_0475|VIRX|202107|202106|202106|||||||||||||||-23.2868||||3.4997|||0||4.7276|||||||||56.0971||||||||||||||||||||||10.52|10.52|278.4402|354491.9667|
new_0222_0475|VIRX|202108|202106|202106|||||||||||||||-19.3146||||3.0743|||0||3.5574|||||||||55.8963||||37.2262||||||||||||||||||9.22|9.22|230.9446|128079.2333|
new_0222_0475|VIRX|202109|202109|202109|113.015|110.983||0.987||12.565|7.161|5.404||98.523|-154.23||||-9.8589||||3.0348|||0||3.0496||2.098|5.456||||||61.3737|37.3534|24|-0.4|37.2812||37.2812|||-0.2929|-0.001|||-107.394|||||3.711|-14.914|-14.914|-0.115|8.02|8.02|198.4902|166385.5|
new_0222_0475|VIRX|202110|202109|202109|||||||||||||||-5.8962||||2.225|||0||2.781|||||||||61.4137||||||||||||||||||||||5.88|5.88|118.7085|148598.6667|
new_0222_0475|VIRX|202111|202109|202109|||||||||||||||-3.5515||||1.7459|||0||1.7941|||||||||61.5017||||37.3117||||||||||||||||||4.61|4.61|71.5019|218189.4333|
new_0222_0475|VIRX|202112|202112|202112|||||||||||||||-1.7723||||1.3823|||0||2.2776|||||||||62.3795||||||||||||||||||||||3.65|3.65|35.6827|310161.4333|
new_0222_0475|VIRX|202201|202112|202112|||||||||||||||0.0253||||1.0149|||0||2.0336|||||||||55.9763||||||||||||||||||||||2.68|2.68|-0.5096|190516.4|
new_0222_0475|VIRX|202202|202112|202112|||||||||||||||-0.6789||||1.1589|||0|||||||||||||||||||||||||||||||||3.06|3.06|13.6688|311334.6333|